Literature DB >> 3207553

Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.

S A Riley1, I A Tavares, A Bennett, V Mani.   

Abstract

1. Delayed-release mesalazine has been formulated to deliver 5-aminosalicylic acid to the colon. We have therefore studied the ileostomy excretion and coat dissolution of this preparation. 2. Following ingestion of a single tablet 88% (range 69-114%) of the 400 mg dose appeared unchanged in the ileosomy effluent over the subsequent 12 h. 3. Ileostomy effluent pH appeared to be a major determinant of 5-aminosalicylic acid release. 4. In vitro studies revealed rapid coat dissolution above pH 7.0, slow dissolution between pH 6.0 and 7.0 and non-dissolution at pH 2.0 and 4.0.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3207553      PMCID： PMC1386524          DOI： 10.1111/j.1365-2125.1988.tb03383.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  14 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

2.  Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.

Authors:  M J Dew; R E Ryder; N Evans; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

3.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

4.  Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).

Authors:  P A van Hees; J H Tuinte; J M van Rossum; J H van Tongeren
Journal:  Gut       Date:  1979-04       Impact factor: 23.059

5.  Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.

Authors:  K M Das; J R Chowdhury; B Zapp; J W Fara
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

6.  Ionic constituents and osmolality of gastric and small-intestinal fluids after eating.

Authors:  J S Fordtran; T W Locklear
Journal:  Am J Dig Dis       Date:  1966-07

7.  Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device.

Authors:  R L Bown; J A Gibson; G E Sladen; B Hicks; A M Dawson
Journal:  Gut       Date:  1974-12       Impact factor: 23.059

8.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

9.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

10.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335
View more
  11 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.

Authors:  S G Nugent; D Kumar; D S Rampton; D F Evans
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

3.  Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).

Authors:  C De Mey; I Meineke
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

4.  Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.

Authors:  F N Hussain; R A Ajjan; M Moustafa; N W Weir; S A Riley
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

5.  Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Hidetaka Sasaki; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

Review 6.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

8.  Oroileal transit of slow release 5-aminosalicylic acid.

Authors:  H Goebell; U Klotz; B Nehlsen; P Layer
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

9.  Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration.

Authors:  Kousaku Kawashima; Shunji Ishihara; Takafumi Yuki; Koji Onishi; Yoshinori Kushiyama; Hirofumi Fujishiro; Youichi Miyaoka; Mika Yuki; Yoshinori Komazawa; Takashi Tanimura; Hiroki Sonoyama; Yasumasa Tada; Ryusaku Kusunoki; Akihiko Oka; Nobuhiko Fukuba; Naoki Oshima; Ichiro Moriyama; Yoshikazu Kinoshita
Journal:  Biomed Res Int       Date:  2014-11-18       Impact factor: 3.411

10.  Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Yoshiyuki Aida; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.